Pier Luigi Zinzani
Pier Luigi Zinzani
Verified email at unibo.it
TitleCited byYear
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by …
M Pfreundschuh, L Trümper, A Österborg, R Pettengell, M Trneny, K Imrie, ...
The lancet oncology 7 (5), 379-391, 2006
19062006
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
M Hallek, K Fischer, G Fingerle-Rowson, AM Fink, R Busch, J Mayer, ...
The Lancet 376 (9747), 1164-1174, 2010
16582010
Follicular lymphoma international prognostic index
P Solal-Céligny, P Roy, P Colombat, J White, JO Armitage, R Arranz-Saez, ...
Blood 104 (5), 1258-1265, 2004
15402004
PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma
AK Gopal, BS Kahl, S de Vos, ND Wagner-Johnston, SJ Schuster, ...
New England Journal of Medicine 370 (11), 1008-1018, 2014
6632014
ALK+ lymphoma: clinico-pathological findings and outcome
B Falini, S Pileri, PL Zinzani, A Carbone, V Zagonel, C Wolf-Peeters, ...
Blood 93 (8), 2697-2706, 1999
6441999
Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
E Zucca, A Conconi, E Pedrinis, S Cortelazzo, T Motta, ...
Blood 101 (7), 2489-2495, 2003
4892003
Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients
SA Pileri, S Ascani, MC Cox, C Campidelli, F Bacci, M Piccioli, ...
Leukemia 21 (2), 340, 2007
4662007
Phase III trial of consolidation therapy with yttrium-90–ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma
F Morschhauser, J Radford, A Van Hoof, U Vitolo, P Soubeyran, H Tilly, ...
Journal of Clinical Oncology 26 (32), 5156-5164, 2008
4482008
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the …
M Pfreundschuh, E Kuhnt, L Trümper, A Österborg, M Trneny, L Shepherd, ...
The lancet oncology 12 (11), 1013-1022, 2011
4412011
T (11; 18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication
H Liu, H Ye, A Ruskone–Fourmestraux, D De Jong, S Pileri, C Thiede, ...
Gastroenterology 122 (5), 1286-1294, 2002
4292002
Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study
OA O'Connor, B Pro, L Pinter-Brown, N Bartlett, L Popplewell, B Coiffier, ...
Journal of clinical oncology 29 (9), 1182, 2011
4222011
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
A Younes, A Santoro, M Shipp, PL Zinzani, JM Timmerman, S Ansell, ...
The lancet oncology 17 (9), 1283-1294, 2016
3902016
An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma
TE Witzig, JM Vose, PL Zinzani, CB Reeder, R Buckstein, JA Polikoff, ...
Annals of Oncology 22 (7), 1622-1627, 2011
3392011
Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score
P Went, C Agostinelli, A Gallamini, PP Piccaluga, S Ascani, E Sabattini, ...
Journal of Clinical Oncology 24 (16), 2472-2479, 2006
3312006
Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients
PL Zinzani, M Magagnoli, P Galieni, M Martelli, V Poletti, F Zaja, S Molica, ...
Journal of Clinical Oncology 17 (4), 1254-1254, 1999
3271999
Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure
P Armand, MA Shipp, V Ribrag, JM Michot, PL Zinzani, J Kuruvilla, ...
Journal of Clinical Oncology 34 (31), 3733, 2016
3192016
ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned
S Viviani, PL Zinzani, A Rambaldi, E Brusamolino, A Levis, V Bonfante, ...
New England Journal of Medicine 365 (3), 203-212, 2011
3082011
Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma
R Chen, PL Zinzani, MA Fanale, P Armand, NA Johnson, P Brice, ...
Journal of Clinical Oncology 35 (19), 2125, 2017
2652017
Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma
PL Zinzani, G Musuraca, M Tani, V Stefoni, E Marchi, M Fina, C Pellegrini, ...
Journal of Clinical Oncology 25 (27), 4293-4297, 2007
2642007
Higher response to lenalidomide in relapsed/refractory diffuse large B‐cell lymphoma in nongerminal center B‐cell–like than in germinal center B‐cell–like phenotype
FJ Hernandez‐Ilizaliturri, G Deeb, PL Zinzani, SA Pileri, F Malik, ...
Cancer 117 (22), 5058-5066, 2011
2552011
The system can't perform the operation now. Try again later.
Articles 1–20